@article{Hassan_Qureshi_Hussain_Gul_Hafizullah_2011, title={ASSESSING THE EFFICACY OF DANSHENFORM COMPOUND IN PATIENTS WITH STABLE ANGINA PECTORIS}, volume={26}, url={https://www.jpmi.org.pk/index.php/jpmi/article/view/1200}, abstractNote={<em><span style="font-family: TimesNewRomanPSMT,BoldItalic; font-size: x-small;"><span style="font-family: TimesNewRomanPSMT,BoldItalic; font-size: x-small;"><span style="font-family: TimesNewRomanPSMT,BoldItalic; font-size: x-small;"><p><strong>Objective</strong><p> </p></p><p><strong> </strong><p> </p><span style="font-family: TimesNewRomanPSMT,Italic; font-size: x-small;"><em></em></span></p><p><span style="font-family: TimesNewRomanPSMT,Italic; font-size: x-small;"><strong>: To assess the efficacy of danshenform compound in patient with angina pectoris already on </strong></span></p><p><strong>optimal dose of anti anginal therapy assessed by exercise tolerance test.</strong><p> </p><em><span style="font-family: TimesNewRomanPSMT,BoldItalic; font-size: x-small;"><span style="font-family: TimesNewRomanPSMT,BoldItalic; font-size: x-small;"><span style="font-family: TimesNewRomanPSMT,BoldItalic; font-size: x-small;"></span></span></span></em></p><p><strong>Methodology</strong><p> </p></p><p><strong> </strong><p> </p></p><p><span style="font-family: TimesNewRomanPSMT,Italic; font-size: xx-small;"><span style="font-family: TimesNewRomanPSMT,Italic; font-size: xx-small;"><strong>th </strong></span></span><span style="font-family: TimesNewRomanPSMT,Italic; font-size: x-small;"><em></em></span></p><p><span style="font-family: TimesNewRomanPSMT,Italic; font-size: x-small;"><strong>week recorded. Total </strong></span></p><p><strong>exercise time, onset of chest pain during exercise, onset of ST segments depression before and after</strong><p> </p></p><p><strong>treatment with Danshenform compound was recorded.</strong><p> </p><p> </p><p> </p><span style="font-family: TimesNewRomanPSMT,Italic; font-size: x-small;"></span></p><p><span style="font-family: TimesNewRomanPSMT,Italic; font-size: x-small;"><strong>: Thirty eight patients with stable angina were included in the study. Patients were exercised </strong></span></p><p><strong>on treadmill according to Bruce protocol at baseline and one week later. At second week, Danshenform</strong><p> </p></p><p><strong>compound 500 mg was prescribed bid for four weeks. At the end of 4 weeks, exercise tolerance test was</strong><p> </p><span style="font-family: TimesNewRomanPSMT,Italic; font-size: x-small;"></span></p><p><strong>performed. Duration and number of anginal episodes before and at the end of 4th </strong><p> </p><em><span style="font-family: TimesNewRomanPSMT,Italic; font-size: x-small;"><em><span style="font-family: TimesNewRomanPSMT,Italic; font-size: x-small;"></span></em></span></em></p><p><strong>week recorded. Total</strong><p> </p></p><p><strong>exercise time, onset of chest pain during exercise, onset of ST segments depression before and after</strong><p> </p><p> </p></p><p><strong>treatment with Danshenform compound was recorded.</strong><p> </p><em><span style="font-family: TimesNewRomanPSMT,BoldItalic; font-size: x-small;"><span style="font-family: TimesNewRomanPSMT,BoldItalic; font-size: x-small;"><span style="font-family: TimesNewRomanPSMT,BoldItalic; font-size: x-small;"><p><strong>Results</strong><p> </p></p><p><span style="font-family: TimesNewRomanPSMT,Italic; font-size: x-small;"><em><p> </p></em></span><p><span style="font-family: TimesNewRomanPSMT,Italic; font-size: x-small;"><strong>: The number of anginal episodes after 4 weeks treatment with danshenform was reduced </strong></span><p><strong>significantly from 4.2+2.4 to 1.4+1.6/week (p=0.001). Time of onset of chest pain improved from 4.63+2.4</strong><p> </p></p><p><strong>to 5.4+3.7 minutes (p=0.35) on exercise tolerance test. Duration of exercise increased from 6.52+1.9</strong><p> </p></p><p><strong>minutes to 8.32+2.3 (p=0.001).Time of onset of ST depression increased from 5.8+1.7 to 7.7+1.6 minutes</strong><p> </p></p><p><strong>(p=0.001) on stress test. Anginal class improved significantly after 4 weeks of treatment with danshenform</strong><p> </p></p><p><strong>compound (p=0.001) with no significant effect on resting heart rate (p=0.58) and systolic blood pressure</strong><p> </p></p><p><strong>(p=0.07) respectively.</strong><p> </p><em><span style="font-family: TimesNewRomanPSMT,BoldItalic; font-size: x-small;"><span style="font-family: TimesNewRomanPSMT,BoldItalic; font-size: x-small;"></span></span></em><p><strong>Conclusion</strong><p> </p></p><p><strong> </strong><p> </p><span style="font-family: TimesNewRomanPSMT,Italic; font-size: x-small;"><em><p> </p></em></span><p><span style="font-family: TimesNewRomanPSMT,Italic; font-size: x-small;">: Danshenform compound is useful in reducing anginal episodes, increasing exercise duration, </span><p>improving functional anginal class, delaying the onset of ST depression on exercise tolerance test in<p> </p><p> </p></p><p>patient with ischemic heart disease.<p> </p></p><p> <p> </p></p></p></p></p></p></p></span></span></span></em></p></span></span></span></em>}, number={1}, journal={Journal of Postgraduate Medical Institute}, author={Hassan, Mahmood ul and Qureshi, Saqib and Hussain, Chiragh and Gul, Adnan Mehmood and Hafizullah, Mohammad}, year={2011}, month={Dec.} }